Curcuma longa L. (turmeric) as adjuvant therapy in childhood idiopathic nephrotic syndrome: A double-blind, randomized, placebo-controlled clinical trial

IF 1.7 Q2 Medicine

Advances in integrative medicine Pub Date : 2024-10-20 DOI:10.1016/j.aimed.2024.10.015

Ivan Coelho Machado , Inalda Facincani , Davi Casale Aragon , Juliana da Silva Coppede , Ana Maria Soares Pereira , Fabio Carmona

{"title":"Curcuma longa L. (turmeric) as adjuvant therapy in childhood idiopathic nephrotic syndrome: A double-blind, randomized, placebo-controlled clinical trial","authors":"Ivan Coelho Machado , Inalda Facincani , Davi Casale Aragon , Juliana da Silva Coppede , Ana Maria Soares Pereira , Fabio Carmona","doi":"10.1016/j.aimed.2024.10.015","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Treating childhood idiopathic nephrotic syndrome (CINS) with steroids can cause significant side effects. <em>Curcuma longa</em> L. (turmeric, Zingiberaceae) has anti-inflammatory activity and may decrease the need for steroid use.</div></div><div><h3>Design/methods</h3><div>Double-blind, placebo-controlled, randomized pilot trial with patients with CINS (1–18 years old) from a single university pediatric nephrology center, receiving a hydroethanolic extract of <em>C. longa</em> rhizomes or placebo for up to 12 months. The primary outcome was the cumulative dose of steroids, and the secondary outcome was the number of relapses. This study is registered in the Clinical Trials Registry (Full ethical details will be provided post-blind review).</div></div><div><h3>Results</h3><div>Between February 2018 and January 2019, 40 patients were recruited and randomized, and 36 were analyzed (18 in <em>C. longa</em> and 18 in placebo groups) in an intention-to-treat analysis. There was no difference between <em>C. longa</em> and placebo in the statistical analysis regarding the cumulative dose of steroids (mean difference: 22.8 mg/m<sup>2</sup>/month, 95 %CrI − 181.9, 210.6) or the incidence of relapses (mean difference: − 0.01 relapses/patient/month, 95 %CrI − 0.08, 0.06). There were no serious adverse events.</div></div><div><h3>Conclusions</h3><div>Compared to placebo, <em>Curcuma longa</em> did not affect the cumulative dose of steroids or the number of relapses in children with CINS.</div></div>","PeriodicalId":7343,"journal":{"name":"Advances in integrative medicine","volume":"12 1","pages":"Pages 87-92"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in integrative medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221295882400140X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Treating childhood idiopathic nephrotic syndrome (CINS) with steroids can cause significant side effects. Curcuma longa L. (turmeric, Zingiberaceae) has anti-inflammatory activity and may decrease the need for steroid use.

Design/methods

Double-blind, placebo-controlled, randomized pilot trial with patients with CINS (1–18 years old) from a single university pediatric nephrology center, receiving a hydroethanolic extract of C. longa rhizomes or placebo for up to 12 months. The primary outcome was the cumulative dose of steroids, and the secondary outcome was the number of relapses. This study is registered in the Clinical Trials Registry (Full ethical details will be provided post-blind review).

Results

Between February 2018 and January 2019, 40 patients were recruited and randomized, and 36 were analyzed (18 in C. longa and 18 in placebo groups) in an intention-to-treat analysis. There was no difference between C. longa and placebo in the statistical analysis regarding the cumulative dose of steroids (mean difference: 22.8 mg/m²/month, 95 %CrI − 181.9, 210.6) or the incidence of relapses (mean difference: − 0.01 relapses/patient/month, 95 %CrI − 0.08, 0.06). There were no serious adverse events.

Conclusions

Compared to placebo, Curcuma longa did not affect the cumulative dose of steroids or the number of relapses in children with CINS.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in integrative medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.20

自引率

11.80%

发文量

审稿时长

15 weeks

期刊介绍： Advances in Integrative Medicine (AIMED) is an international peer-reviewed, evidence-based research and review journal that is multi-disciplinary within the fields of Integrative and Complementary Medicine. The journal focuses on rigorous quantitative and qualitative research including systematic reviews, clinical trials and surveys, whilst also welcoming medical hypotheses and clinically-relevant articles and case studies disclosing practical learning tools for the consulting practitioner. By promoting research and practice excellence in the field, and cross collaboration between relevant practitioner groups and associations, the journal aims to advance the practice of IM, identify areas for future research, and improve patient health outcomes. International networking is encouraged through clinical innovation, the establishment of best practice and by providing opportunities for cooperation between organisations and communities.